BMT2: A Non-Code RNA Molecule with Potential Therapeutic Applications

Target Name: BMT2

NCBI ID: G154743

BMT2

BMT2: A Non-Code RNA Molecule with Potential Therapeutic Applications

BMT2, also known as probable methyltransferase BTM2 homolog, is a non-coding RNA molecule that has been identified as a potential drug target or biomarker. The molecule is a key player in the epigenetic regulation of gene expression and has been shown to play a critical role in the development and progression of various diseases, including cancer.

BMT2 is a highly conserved non-coding RNA molecule that is expressed in a variety of tissues and cells, including brain, spinal cord, and peripheral tissues. It is characterized by a unique N-terminal region that contains a conserved core sequence and a C-terminal region that is highly conserved but contains several potential binding sites for protein partners.

The N-terminal region of BMT2 contains a core sequence that is highly conserved across different species and is thought to be involved in the regulation of gene expression. This region has been shown to play a role in the regulation of various gene expression pathways, including those involved in cell adhesion, migration, and survival.

The C-terminal region of BMT2 is also conserved across different species and contains several potential binding sites for protein partners. This region has been shown to play a role in the regulation of various gene expression pathways, including those involved in cell adhesion, migration, and survival.

BMT2 has been shown to play a critical role in the development and progression of various diseases, including cancer. For example, studies have shown that high levels of BMT2 are associated with poor prognosis in cancer patients. Additionally, research has also shown that inhibition of BMT2 has been shown to be a potential therapeutic approach for treating various diseases, including cancer.

In addition to its potential therapeutic applications, BMT2 has also been shown to be a potential biomarker for a variety of diseases. For example, studies have shown that levels of BMT2 have been shown to be elevated in the blood of patients with various diseases, including cancer. Additionally, research has also shown that levels of BMT2 have been shown to be reduced in the blood of patients with certain diseases, such as Alzheimer's disease.

BMT2 has also been shown to play a critical role in the regulation of stem cell proliferation and differentiation. For example, studies have shown that BMT2 is involved in the regulation of stem cell self-renewal and that inhibition of BMT2 has been shown to be a potential therapeutic approach for treating stem cell-derived diseases, such as cancer.

In conclusion, BMT2 is a non-coding RNA molecule that has been shown to play a critical role in the regulation of gene expression and has been identified as a potential drug target or biomarker. Further research is needed to fully understand the role of BMT2 in the development and progression of various diseases and to determine its potential as a therapeutic approach.

Protein Name: Base Methyltransferase Of 25S RRNA 2 Homolog

Functions: S-adenosyl-L-methionine-binding protein that acts as an inhibitor of mTORC1 signaling via interaction with the GATOR1 and KICSTOR complexes (PubMed:29123071). Acts as a sensor of S-adenosyl-L-methionine to signal methionine sufficiency to mTORC1: in presence of methionine, binds S-adenosyl-L-methionine, leading to disrupt interaction with the GATOR1 and KICSTOR complexes and promote mTORC1 signaling (PubMed:29123071). Upon methionine starvation, S-adenosyl-L-methionine levels are reduced, thereby promoting the association with GATOR1 and KICSTOR, leading to inhibit mTORC1 signaling (PubMed:29123071). Probably also acts as a S-adenosyl-L-methionine-dependent methyltransferase (Potential)

The "BMT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BMT2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets